Entero Therapeutics, Inc. (NASDAQ:ENTO) Sees Large Increase in Short Interest

Entero Therapeutics, Inc. (NASDAQ:ENTO) saw a significant growth in short interest in the month of March. As of March 15th, there was short interest totalling 142,800 shares, a growth of 48.8% from the February 28th total of 96,000 shares. Based on an average trading volume of 222,800 shares, the days-to-cover ratio is presently 0.6 days. Currently, 3.1% of the shares of the stock are sold short.

Entero Therapeutics Stock Down 0.1 %

Entero Therapeutics stock opened at $0.48 on Tuesday. Entero Therapeutics has a 1-year low of $0.19 and a 1-year high of $3.16. The firm’s 50 day simple moving average is $0.52 and its 200 day simple moving average is $0.53.

Entero Therapeutics Company Profile

Entero Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of targeted and orally delivered therapies for the treatment of patients with gastrointestinal diseases. The company's pipeline candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides, currently under Phase 2 studies; and capeserod, a selective 5-HT4 receptor partial agonist under Phase 1 studies for the treatment of gastroparesis.